Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by scarlet1967on Apr 08, 2021 1:09pm
64 Views
Post# 32957473

RE:RE:RE:RE:RE:RE:RE:So far so good

RE:RE:RE:RE:RE:RE:RE:So far so good I believe you and myself together with other existing shareholders make a lot of efforts to understand the prospects of the company as we are already committed, what other choices do we have? the trick is to attract more investors not needing to google scientific information, potential revenues etc day in day out.

Lee430 wrote: I must admit most of the science is above me, however, I do make an effort to read and understand what I can...that said the info does keep me engaged and helps keep me confident in my decision to maintain my embarrassingly overweight position in Thera….Unfortunately if I was relying solely on the minimal updates from Thera to make my decisions I most likely would have at least trimmed my position long ago.


scarlet1967 wrote: The fact that few people understand the science here and elsewhere and most of them are shareholders doesn't justify not trying to explain it to thousands of investors who are NOT shareholders of the company, not yet.
Investors  needs to understand the value of their science to be able to validate their decision to start investing in the company. The value of the science is the science itself and the future potential revenues of it.
The company's IR department has to make it easy for people invest their hard earned money in the company, upgraded and timely updated  website, frequent flow of information by PRs, webcasts, conferences(retail or institution oriented) by "marketing aces"  are  must to do things which should be in company's agenda on regular basis failing that we will be stuck with low valuation and volume which will be putting folks off. It's simple only when they start believing in it.




<< Previous
Bullboard Posts
Next >>